Insiders have been trading these 5 stocks: ((JPM)), ((CVX)), ((MSTR)), ((MRNA)) and ((SNAP)). Here is a breakdown of their recent trades and their value.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Corporate Shake-Up: Goldman Sachs GC Stacey Friedman turned heads after selling 5,468 shares of JPMorgan Chase stock in a transaction valued at $1,641,821. Investors are now watching closely to see whether this sizable sale signals a shift in sentiment around JPMorgan Chase or reflects personal portfolio rebalancing by the influential executive.
Energy giant Chevron also saw notable insider activity as Director John Hess unloaded 380,000 shares of Chevron stock. With the sale totaling a massive $73,412,808, market watchers are parsing the move for clues about the director’s outlook on Chevron’s future performance and the broader energy sector.
In a pair of smaller but notable trades, Director Jarrod Patten trimmed his position in Strategy stock through two separate sales. He first sold 5,250 shares worth $875,087, followed by another sale of 1,500 shares valued at $286,280, raising questions about internal expectations for Strategy’s next phase.
Biotech favorite Moderna was not left out of the insider action, as Director Noubar Afeyan sold 9,263 shares of Moderna stock. The transaction, worth $433,878, has sparked fresh debate over how insiders are positioning themselves after Moderna’s volatile run and what it might mean for upcoming catalysts in the pipeline.
Snap saw a flurry of executive selling, led by CAO Rebecca Morrow offloading 16,729 shares for $93,515 and CBO Ajit Mohan selling 44,785 shares for $250,796. Adding to the wave, GC Zachary M Briers sold 129,493 shares worth $725,160, while CFO Douglas Hott disposed of 124,209 shares valued at $695,570, collectively raising eyebrows across the tech-investing community.